The latest price target for Tempest Therapeutics (NASDAQ:TPST) was reported by Scotiabank on April 10, 2025. The analyst firm set a price target for $9.00 expecting TPST to rise to within 12 months (a possible 209.28% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Tempest Therapeutics (NASDAQ:TPST) was provided by Scotiabank, and Tempest Therapeutics downgraded their sector perform rating.

There is no last upgrade for Tempest Therapeutics

The last downgrade for Tempest Therapeutics Inc happened on April 10, 2025 when Scotiabank changed their price target from $7 to $9 for Tempest Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tempest Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tempest Therapeutics was filed on April 10, 2025 so you should expect the next rating to be made available sometime around April 10, 2026.

While ratings are subjective and will change, the latest Tempest Therapeutics (TPST) rating was a downgraded with a price target of $7.00 to $9.00. The current price Tempest Therapeutics (TPST) is trading at is $2.91, which is out of the analyst’s predicted range.